Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/12/2026

Standardized MRI Protocol for Adult Brain Tumor Evaluation

Core Imaging Recommendations

  • MRI of the brain with and without intravenous contrast using a standardized Brain Tumor Imaging Protocol (BTIP) is the gold‑standard study for adults with suspected brain tumors. The American College of Radiology endorses this approach. 1
  • High‑resolution 3‑D T1‑weighted imaging performed before and after contrast administration is the single most critical sequence for tumor visualization, delineation of tumor extent, and surgical planning. Strong recommendation. 1
  • Axial 2‑D T2 FLAIR is essential to assess vasogenic edema, tumor‑related parenchymal changes, and leptomeningeal involvement. Strong recommendation. 1
  • Axial diffusion‑weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps provides information on tumor cellularity and helps differentiate tumor from abscess or other non‑neoplastic lesions. Strong recommendation. 1
  • Axial susceptibility‑weighted imaging (SWI) is critical for detecting intratumoral calcifications, hemorrhage, and abnormal vascular structures. Strong recommendation. 1
  • Axial T2‑weighted sequences add complementary anatomic detail to the protocol. Strong recommendation. 1

Role of Contrast Administration

  • Contrast‑enhanced MRI is mandatory; non‑contrast MRI alone is insufficient for clinical decision‑making in brain tumor patients. Evidence level: high (guideline‑based). 2
  • Contrast enhancement reflects blood‑brain‑barrier disruption and yields enhancement patterns that aid pre‑operative differential diagnosis and stratify tumors into high‑ versus low‑grade categories. Strong recommendation. 1

Advanced Adjunct Sequences

Adjunct Technique Primary Clinical Utility Evidence Highlights
Perfusion MRI (DSC or ASL) • Differentiates high‑grade from low‑grade gliomas (sensitivity ≈ 100 % in pediatric studies)
• Distinguishes primary CNS lymphoma from glioblastoma and metastases
• Predicts overall survival and guides optimal biopsy targeting
• Identifies metabolic hotspots for tissue sampling
High sensitivity for grade discrimination; rCBV correlates with improved overall survival in glioblastoma. [1]
MR Spectroscopy (MRS) Increases diagnostic certainty by detecting characteristic metabolite patterns; when combined with perfusion, predicts molecular markers such as IDH mutation and 1p/19q co‑deletion. Moderate‑to‑high evidence. [3]
Functional MRI (fMRI) & Diffusion Tensor Imaging (DTI) Facilitates surgical planning for tumors involving eloquent brain regions, helping preserve critical neurological function. Strong recommendation. [1]
  • Relative cerebral blood volume (rCBV) derived from DSC‑MRI predicts improved overall survival in glioblastoma patients. High‑level evidence. 1

Location‑Specific Protocol Adjustments

  • Intra‑axial (parenchymal) tumors: The full standardized BTIP is mandatory; add post‑contrast 3‑D T2 FLAIR to evaluate leptomeningeal metastases, which influences management and survival. 1
  • Extra‑axial (dural‑based) tumors: The same contrast‑enhanced BTIP applies. 4

Imaging Standardization and Workflow

  • All MRI datasets should be converted to a digital format (e.g., CD/DVD) to enable subsequent dosimetric studies and treatment planning. 5
  • Uniform acquisition protocols are essential for enrollment in multicenter clinical trials. 1

Interpretation Pitfalls

  • Pseudoprogression: Early post‑radiotherapy imaging changes (within the first months) may mimic tumor progression but should not be automatically interpreted as treatment failure. 6

Timing of Post‑operative Imaging

  • Post‑operative MRI should be performed within 72 hours after surgical resection to assess residual tumor and establish a new baseline for surveillance. 5

Brain Tumor Detection and Characterization with MRI

Detection Capability

  • Vasogenic edema and mass effect associated with brain tumors are visible on non-contrast MRI sequences, allowing for detection of both primary and metastatic brain tumors 7, 8, 9, 10
  • Discrete lesions can often be directly visualized on T2-weighted and FLAIR sequences, particularly larger tumors 7, 9, 10
  • T2/FLAIR imaging can reveal the presence of abnormal tissue and help assess tumor location 7, 8

Critical Limitations Without Contrast

  • The American College of Radiology explicitly states that MRI brain without IV contrast is insufficient to adequately delineate tumor extent and characteristics 11
  • IV contrast is typically preferred for improved delineation of both intraaxial and extraaxial lesions 7, 9, 10
  • Both primary and metastatic brain tumors often demonstrate enhancing disease due to leaky vasculature from blood-brain barrier disruption, which is best shown on post-contrast T1 imaging 11
  • Contrast enhancement provides critical information about tumor extent, tissue involvement, vascular involvement, and associated mass effect 8, 9, 10
  • Enhancement patterns help with preoperative differential diagnosis and stratification into high- versus low-grade tumors, though enhancement doesn't always correlate with WHO grade 8, 9, 10

Standard of Care Recommendations

  • The American College of Radiology recommends MRI brain without and with IV contrast as the standard of care for brain tumor detection and characterization 11, 7, 8
  • For screening in high-risk patients, MRI brain without and with IV contrast is recommended 11
  • For pretreatment evaluation of suspected brain tumors, MRI brain without and with IV contrast is recommended 11, 8, 9
  • For posttreatment surveillance, MRI brain without and with IV contrast is recommended 11, 12, 13

Common Pitfall to Avoid

  • The American College of Radiology advises against relying on non-contrast MRI for clinical decision-making about brain tumors, as it cannot accurately determine tumor extent, differentiate tumor from other pathologies, assess for leptomeningeal or dural involvement, distinguish recurrent tumor from post-treatment changes, or guide treatment decisions 8, 9, 11, 12

REFERENCES

1

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

2

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

3

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

4

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

7

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

8

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

9

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

10

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

11

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

12

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025

13

acr appropriateness criteria® brain tumors. [LINK]

Journal of the American College of Radiology, 2025